IGFBP2 and glioma: Because of its overexpression, soluble IGFBP2 represents a good diagnostic and prognostic biomarker in several advanced cancers such as breast, glioma, ovarian, and lung cancer, eliciting a B cell-mediated immune response with the production of anti-IGFBP2 antibodies [18,19,20].